Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4‐fluoroamphetamine intoxication
Patrick C. Dolder, Elizabeth B. de Sousa Fernandes Perna, Natasha L. Mason, Nadia R. P. W. Hutten, Stefan W. Toennes, Eef L. Theunissen, Johannes G. Ramaekers, Kim P. C. Kuypers
Human Psychopharmacology Clinical and Experimental October 25, 2018 DOI: 10.1002/hup.2680 via OpenAlex
Summary
AI-generated from the abstract4-Fluoroamphetamine (4-FA), a novel psychoactive substance with effects between MDMA and amphetamine, reduced cognitive empathy while leaving emotional empathy unaffected in healthy poly-drug users. Plasma oxytocin levels increased one hour after a 100 mg dose compared with placebo, but this hormonal change was unrelated to the behavioral effects on empathy. The findings indicate that 4-FA affects empathy differently from MDMA and amphetamine, and confirm that drug-induced changes in peripheral oxytocin are not associated with empathy.
Study at a glance
| Characteristics | Double-blind placebo-controlled two-way crossover study Peer reviewed |
|---|---|
| Sample size | 12 |
| Population | Healthy poly-drug users |
| Intervention | 4-Fluoroamphetamine (4-FA) |
| Dose | 100 mg |
| Topics | MDMA |
| Keywords | Empathy Oxytocin Placebo Amphetamine |
| Citations | 6 |
| Key finding | 4-FA reduced cognitive empathy but did not affect emotional empathy, and increased oxytocin levels independently of behavioral effects. |
Abstract
OBJECTIVES: 4-Fluoroamphetamine (4-FA) is a novel psychoactive substance with a pharmacological profile and reported subjective effects (e.g., empathy) intermediate between 3,4-methylenedioxymethamphetamine (MDMA) and amphetamine. Studies have shown that MDMA and amphetamine increase emotional empathy without affecting cognitive empathy; MDMA simultaneously leads to elevated levels of oxytocin, unrelated to its behavioral effects. The aim of the present study was to assess the reported enhancement of empathy by 4-FA, to assess its effects on oxytocin, and to test potential associations between both. METHODS: Twelve healthy poly-drug users were included in a double-blind placebo-controlled two-way crossover study. Treatments were 4-FA (100 mg) and placebo; empathy was assessed by means of the multifaceted empathy test, and blood samples were taken before and after treatment administration to determine oxytocin concentrations. RESULTS: 4-FA reduced cognitive empathy, whereas emotional empathy was left unaffected. One hour after treatment, plasma oxytocin levels were significantly increased compared with placebo. Behavioral and hormonal effects were unrelated. CONCLUSION: Although 4-FA shares its pharmacological mechanism with MDMA and amphetamine, current findings seem to indicate that it affects empathy differently. The 4-FA-induced increase in oxytocin levels was independent of behavioral effects, which confirms previous findings that drug-induced effects on peripheral oxytocin levels are not associated with empathy.